The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
Approximately 3 million critically ill patients are intubated and initiated on mechanical ventilation each year in the United States. A critical component of mechanical...
Hyperkalemia is a life-threatening electrolyte disorder that is commonly encountered in the ED and ICU. In this podcast we review the latest evidence in...
Peds EM superstars Mimi Lu and Barrie Bostick join CCPEM to review the latest clinical guidelines on hemodynamic support of pediatric and neonatal septic...
